In an interview to CNBC-TV18, Amey Chalke, Pharma Analyst at HDFC Securities shared his readings and outlook on Divis Laboratories and Dr Reddys Laboratories.
Chalke assumes 15-20 percent cut in FY18 and FY19 earnings per share (EPS) estimates on Divis Labs.
Speaking about Dr Reddys, he says some of the observations on Dr Reddy's Duvvada unit look critical in nature and company may take some time to resolve issues with regards to Duvvada observations, he adds.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
